Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJinming Yu
About this trial
This phase III trial compares the effect of adding radiation therapy to the usual maintenance therapy with adebrelimab versus adebrelimab alone in patients who have already received debrelimab plus chemotherapy for the treatment of extensive stage small cell lung cancer.
Eligibility criteria
Qualifiers
Aged 18-75 years, male or female;
Histologically or cytologically confirmed extensive stage small cell lung cancer (according to the Veterans Lung Administration Lung Study Group, VALG stage);
ECOG performance status score 0 ~ 1;
No prior line of systemic therapy for ES-SCLC;
Disqualifiers
Histologically or cytologically determined as a mixed pathological type with components such as non-small cell lung cancer;
Active or untreated CNS metastases detected by computed tomography (CT) or magnetic resonance imaging (MRI) during the screening period and previous imaging assessments;
Spinal cord compression that is not relieved by surgery and/or radiotherapy;
Clinically symptomatic third space effusion requiring repeated drainage within 2 weeks, such as pericardial effusion, pleural effusion, and abdominal effusion that are still uncontrollable by pumping or other treatments;
Trial design
Treatments tested in this trial
- Adebrelimab
- Radiation Therapy
Treatment groups
524 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Jinming Yu
Lead sponsor
Shandong Cancer Hospital and Institute
Sponsor institution
Source ClinicalTrials.gov